Diomed and BSN-JOBST Form Sales & Marketing Alliance
May 16 2006 - 10:40AM
Business Wire
Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer
of minimally invasive medical technologies, including its patented
EndoVenous Laser Treatment (EVLT(R)) for varicose veins, today
announced the formation of a strategic marketing and sales alliance
for the US vein care market with BSN-JOBST, Inc., the manufacturer
of JOBST medical compression garments. JOBST is the market leader
and number one physician recommended brand of medical compression
garments in the US. Medical compression therapy is an important
modality used for the care and management of venous and lymphatic
disease. Compression therapy is frequently recommended by
physicians prior to EndoVenous Laser Treatment of varicose veins
and, following Endovenous Laser Treatment, patients are required to
wear graduated compression stockings for a week to ten days. Under
the terms of the multi-year agreement, the two companies will
provide joint training activities for physicians, conduct sales
force cross-training, and implement a lead sharing program and
other co-marketing activities. The agreement will result in sales
collaboration and co-marketing activities in the United States to
advance the sales of each company's respective products into the
rapidly growing vein care marketplace. "This agreement combines the
strengths of two market leaders," stated Jake Newman, Director of
Marketing at BSN-JOBST, Inc. "Since Conrad Jobst introduced our
first product over 50 years ago, we have been focused upon
improving the quality of life for those who suffer from venous
disease. With Diomed's leadership position in the endovenous laser
treatment of varicose veins, we believe the synergies between our
companies will benefit patients and physicians alike." "We are
pleased to be joining JOBST in this important marketing alliance,"
stated James A. Wylie, Diomed's President and Chief Executive
Officer. "JOBST is the #1 physician recommended brand of medical
compression stockings, backed by over 50 years of experience and an
ideal partner in the management of venous disease. In the last
year, Diomed has launched the DELTA Laser system, introduced the
SpotLight(TM) sheath, obtained distribution rights for the
revolutionary VeinViewer(TM) by Luminetx, and established a
marketing and education alliance with Sonosite, the leader in hand
held ultrasound systems. This agreement with Jobst provides yet
another solid example of Diomed's commitment to providing its
customers with comprehensive solutions for treating vein disease."
About Diomed Diomed develops and commercializes minimal and
micro-invasive medical procedures that use its proprietary laser
technologies and disposable products. Diomed's EVLT(R) laser vein
ablation procedure is used in varicose vein treatments. Diomed also
provides photodynamic therapy (PDT) for use in cancer treatments,
and dental and general surgical applications. The EVLT(R) procedure
and the Company's related products were cleared by the United
States FDA in January of 2002. Along with lasers and single-use
procedure kits for its EVLT(R) laser vein treatment, the Company
provides its customers with state of the art physician training and
practice development support. Additional information is available
on the Company's website: www.evlt.com. EVLT(R) is a registered
trademark of Diomed Inc., Andover, MA. Safe Harbor Safe Harbor
statements under the Private Securities Litigation Reform Act of
1995: Statements in this news release looking forward in time
involve risks and uncertainties, including the risks associated
with trends in the products markets, reliance on third party
distributors in various countries outside the United States,
reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These
statements relate to our future plans, objectives, expectations and
intentions. These statements may be identified by the use of words
such as "may," "will," "should," "potential," "expects,"
"anticipates," "intends," "plans," "believes" and similar
expressions. These statements are based on our current beliefs,
expectations and assumptions and are subject to a number of risks
and uncertainties. Our actual results could differ materially from
those discussed in these statements. Our Annual Report on Form SEC
10-KSB/A (the "Annual Report") contains a discussion of certain of
the risks and uncertainties that affect our business. We refer you
to the "Risk Factors" on pages 23 through 38 of the Annual Report
for a discussion of certain risks, including those relating to our
business as a medical device company without a significant
operating record and with operating losses, our risks relating to
our commercialization of our current and future products and
applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct
any of its forward-looking statements.
Diomed (AMEX:DIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diomed (AMEX:DIO)
Historical Stock Chart
From Jul 2023 to Jul 2024